Canaccord Genuity Remains Bullish Following Globus Medical (GMED) Marketing Meetings

Canaccord Genuity maintains a Buy rating and $31 price target on Globus Medical (NYSE: GMED) after meeting with management. Analyst William Plovanic believes that Globus is well positioned to outgrow the market.

Plovanic commented on GMED, saying, "We reiterate our BUY rating on Globus post marketing meetings with management. We are more bullish on the stock post the meetings, as we believe the macro for the US spine market continues to improve and Globus is well positioned to outgrow the market. Further, we believe Globus’ ability to continue to take share and generate strong operating margins reinforces our thesis that the company offers investors multiple opportunities to create value."

For an analyst ratings summary and ratings history on Globus Medical click here. For more ratings news on Globus Medical click here.

Shares of Globus Medical closed at $25.80 yesterday.

You May Also Be Interested In

• HSBC Downgrades Feng Tay Enterprises (9910:TT) to Hold
• Lithium Americas Corp (LAC) Prices 55M Share Offering at $5/sh
• B.Riley Resumes PubMatic Inc (PUBM) at Buy